{"ticker": {"uuid": "6ea5a144-2e3f-4d8f-83ba-cc06b4773051", "symbol": "CAMP", "name": "CAMP4 THERAPEUTICS CORPORATION", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T12:53:38+00:00", "published_display": "18 Jul 2026 12:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "CAMP4 Therapeutics announced a non-qualified stock option grant to a new employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant involves 8,000 shares at an exercise price of $4.21 per share and will vest over a four-year period. This", "url": "https://www.globenewswire.com/fr/news-release/2026/07/17/3329275/0/en/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-18T04:10:55", "published_display": "18 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 New Hire Gets Option on 8,000 Shares at $4.21", "summary": "CAMP4 Therapeutics announced that its Board Compensation Committee granted a non-qualified stock option to a new employee to purchase 8,000 shares of common stock at an exercise price of $4.21 per share. This inducement grant, made under Nasdaq Listing Rule 5635(c)(4), has a 10-y", "url": "https://www.stocktitan.net/news/CAMP/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-qj27rqb7iosu.html", "source_name": "Stock Titan", "published_at": "2026-07-17T19:41:38", "published_display": "17 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?", "summary": "JPMorgan upgraded CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) to Overweight with a price target of $9, citing the potential undervaluation given the promise of CMP-002 for SYNGAP1-related disorder. The company also announced positive preclinical results for CMP-002, showing impr", "url": "https://www.insidermonkey.com/blog/is-camp4-therapeutics-corporation-camp-stock-undervalued-ahead-of-key-cmp-002-clinical-development-milestones-1793951/", "source_name": "Insider Monkey", "published_at": "2026-07-02T16:06:00", "published_display": "02 Jul 2026 16:06", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8 Best Up and Coming Pharmaceutical Stocks to Buy Now", "summary": "The article highlights CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) as a promising pharmaceutical stock, noting JPMorgan's upgrade to Overweight with a $9 price target due to potential of CMP-002 for SYNGAP1-related disorder. CAMP4's preclinical findings for CMP-002 showed signif", "url": "https://www.insidermonkey.com/blog/8-best-up-and-coming-pharmaceutical-stocks-to-buy-now-1792190/2/", "source_name": "Insider Monkey", "published_at": "2026-06-30T18:04:00", "published_display": "30 Jun 2026 18:04", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of CAMP4 Therapeutics Corp (CAMP), noting its current valuation score of 6.02, which ranks 364 out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -1.79, indicating a significant deviation from it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-26T21:09:20", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP - CAMP4 Therapeutics Corp Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for CAMP4 Therapeutics Corp (CAMP), including its last close price, market capitalization, income, sales, key financial ratios, and performance metrics. It lists insider and institutional ownership, profitability margins, and s", "url": "https://finviz.com/stock?t=CAMP&ta=1&p=d&ty=rv&b=2", "source_name": "Finviz", "published_at": "2026-06-23T09:39:56", "published_display": "23 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 lures 3 new hires with 39,000 stock options", "summary": "CAMP4 Therapeutics (Nasdaq:CAMP) has granted 39,000 non-qualified stock options to three new employees as an inducement to join the company. These options, with an exercise price of $3.96 per share, vest over four years with a 10-year term. This move aligns with Nasdaq Listing Ru", "url": "https://www.stocktitan.net/news/CAMP/camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-0o0c8fzbzbaj.html", "source_name": "Stock Titan", "published_at": "2026-06-19T20:09:17", "published_display": "19 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "CAMP4 Therapeutics, a clinical-stage biopharmaceutical company, announced stock option grants to three new employees as an inducement to employment. These grants, totaling 39,000 shares, are in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $3.96 per", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314891/0/en/camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T16:05:00", "published_display": "19 Jun 2026 16:05", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Institutional Confidence", "summary": "CAMP4 Therapeutics Corp (CAMP) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. This score reflects an institutional shareholding proportion of 82.01%, a quarter-over-quarter increase of 237.71%. Steven ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T16:40:16", "published_display": "18 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "TradingKey reports that CAMP4 Therapeutics Corp (CAMP) has a current financial score of 6.62, ranking 235 out of 388 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently saw a 50.82% year-over-year", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:12:59", "published_display": "18 Jun 2026 06:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "CAMP4 Therapeutics Corp (CAMP) has an earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry. Analysts have an average price target of $7.50 for the stock, with a consensus \"Buy\" rating based on 7 analysts. The company's expected revenue fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:12:59", "published_display": "18 Jun 2026 05:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides details on the dividend and stock split history for CAMP4 Therapeutics Corp (CAMP). It indicates that the company has distributed $0.00 in dividends over the past five years and has no historical stock split data available. The page also presents current sto", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T11:09:28", "published_display": "17 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Shares Rise After JPMorgan Upgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/camp4-therapeutics-shares-rise-jpmorgan-185644276.html", "source_name": "MT Newswires", "published_at": "2026-06-16T18:56:44+00:00", "published_display": "16 Jun 2026 18:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Upgrades CAMP4 Therapeutics to Overweight From Neutral, Adjusts PT to $9 From $5", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-upgrades-camp4-therapeutics-overweight-091952324.html", "source_name": "MT Newswires", "published_at": "2026-06-16T09:19:52+00:00", "published_display": "16 Jun 2026 09:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential", "summary": "JPMorgan has upgraded CAMP4 Therapeutics Corp (NASDAQ:CAMP) to Overweight and raised its price target to $9.00, citing the potential of its drug candidate CMP-002 for SYNGAP1-related disorder. The firm believes the stock is undervalued, anticipating CMP-002 will enter clinical tr", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-upgrades-camp4-therapeutics-stock-rating-on-cmp002-potential-93CH-4743907", "source_name": "Investing.com", "published_at": "2026-06-16T05:39:13", "published_display": "16 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike", "summary": "Camp4 Therapeutics director Stewart Murray was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. These options will vest fully on the earlier of the first anniversary of the grant date or the company's next annual meeting of stockho", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-95b370c4c6ff.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:13:38", "published_display": "16 Jun 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics director granted 28K options | CAMP Insider Trading", "summary": "Camp4 Therapeutics director and 10% owner Amir Nashat was granted 28,000 stock options with an exercise price of $4.34 per share; no cash was paid at the time of the grant. The options vest fully on the earlier of the first anniversary of the grant date or the company's next annu", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-0f0b08800288.html", "source_name": "Stock Titan", "published_at": "2026-06-13T02:09:16", "published_display": "13 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics (CAMP) director awarded 28,000 stock options", "summary": "Camp4 Therapeutics (CAMP) director Douglas E. Williams was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options will fully vest on the earlier of the first anniversary of the grant date or the company's next annual meeting,", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-fd33bb0225d3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:16", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics (CAMP) grants director 28,000 stock options", "summary": "Camp4 Therapeutics Corp. director Richard A. Young was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the company's next annual meeting, continge", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-121edaf1222b.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:16", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics director granted 28,000 options | CAMP Insider Trading", "summary": "Camp4 Therapeutics director Steven H. Holtzman was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options will vest on the earlier of the first anniversary of the grant date or the company's next annual shareholder meeting, p", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-7d7e34867096.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:16", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan initiates CAMP4 Therapeutics stock with buy rating", "summary": "Chardan has initiated coverage on CAMP4 Therapeutics with a buy rating and a price target of $6.50, citing significant upside potential from its current trading price of $4.01. The biotechnology company, specializing in antisense oligonucleotides for neurodevelopmental disorders ", "url": "https://m.uk.investing.com/news/stock-market-news/chardan-initiates-camp4-therapeutics-stock-with-buy-rating-93CH-4721222?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T13:09:47", "published_display": "11 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan initiates CAMP4 Therapeutics stock with buy rating By Investing.com", "summary": "Chardan has initiated coverage on CAMP4 Therapeutics (NASDAQ:CAMP) with a buy rating and a price target of $6.50, citing significant upside potential from its current trading price of $4.01. The clinical-stage biotechnology company, supported by research from MIT's Whitehead Inst", "url": "https://au.investing.com/news/stock-market-news/chardan-initiates-camp4-therapeutics-stock-with-buy-rating-93CH-4479945", "source_name": "Investing.com Australia", "published_at": "2026-06-11T02:40:35", "published_display": "11 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP Initiated Coverage by Chardan Capital -- Rating Set to Buy", "summary": "Chardan Capital has initiated coverage on Camp4 Therapeutics (CAMP) with a \"Buy\" rating and a price target of $6.50, citing the company's pioneering work in RNA-based therapeutics for genetic diseases. Despite this positive outlook, Camp4 Therapeutics holds a low GF Score\u2122 of 8/1", "url": "https://www.gurufocus.com/news/8909851/camp-initiated-coverage-by-chardan-capital-rating-set-to-buy?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-10T15:09:47", "published_display": "10 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Initiates Camp4 Therapeutics at Buy With $6.50 Price Target", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/chardan-initiates-camp4-therapeutics-buy-104423485.html", "source_name": "MT Newswires", "published_at": "2026-06-10T10:44:23+00:00", "published_display": "10 Jun 2026 10:44", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation", "summary": "Camp4 Therapeutics (NASDAQ:CAMP) has seen its stock rise 114% in the last year despite not yet making a profit. The company has a cash runway of 3.8 years, with $99 million in cash and a cash burn of $26 million in the past year. Analysts are optimistic about its revenue growth o", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-were-not-too-125746501.html", "source_name": "Market source", "published_at": "2026-06-06T12:39:37", "published_display": "06 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP - CAMP4 Therapeutics Corp Options", "summary": "This page provides a detailed financial overview of CAMP4 Therapeutics Corp (CAMP), including its stock performance, key financial metrics, and company statistics. It covers areas such as market capitalization, income, sales, insider and institutional ownership, and various perfo", "url": "https://finviz.com/stock?t=CAMP&ty=oc", "source_name": "Finviz", "published_at": "2026-06-02T22:39:58", "published_display": "02 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP - CAMP4 Therapeutics Corp Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news for CAMP4 Therapeutics Corp (CAMP). It details the company's stock price, market capitalization, income, sales, and various financial ratios, along with insider transac", "url": "https://finviz.com/stock?t=CAMP", "source_name": "Finviz", "published_at": "2026-06-01T10:09:58", "published_display": "01 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New CAMP4 hire receives 5,000-share stock option grant", "summary": "CAMP4 Therapeutics (Nasdaq: CAMP) announced it granted a non-qualified stock option to a new employee to purchase 5,000 shares of common stock. This inducement award, granted under Nasdaq Listing Rule 5635(c)(4), has a 10-year term and an exercise price of $4.31, vesting over fou", "url": "https://www.stocktitan.net/news/CAMP/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-5w6x7yz1cca2.html", "source_name": "Stock Titan", "published_at": "2026-05-24T08:09:42", "published_display": "24 May 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNcE5WUGt0NDM0bmpUUUZ0RlZ1Y3VaNk5HNVE0dEEtU0dPVmF3bU9jMFdxTGJ6MjdtZ0psVnNvX3JrM0ZOdWtHOWtnRnJQZ3M3Y2Q4U0FNV2hkQXNocy1yMGRlTDZRdTV1cVZscDc1Vmg2Z0M1YzBVZXZDNDZocVhQRW9jeGNLRXJMNm5qLUQ3Tm9lYzdFeVBkSVBFbUhkRWFxbVFid2hTVTlDQ2NqMm9SRjdJeFNJUzNCc3lPdHZWZ3dwZjhEWUJqYkV5Z0VOSWoxTURVREVjVlNpVXNmLWdlQw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Three new CAMP4 hires get stock options at $4.59 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQRi00WGdqb1pTNUs4bjUyZXd5azExd05aVWF4ekN0OTVGYm9sSHFibW9hZDV2Y3BHeGIxU1hRMHNBZDc1VDFfbml2X0NFUXNvcDF5Tll0eUpENWw3blVFNmVES2hKN1pfcE9BN01yS01hSWdXZllSUFBnLVdhTVVObW9ndWpIWi12WlI1d2pzaWo1cHEyUVJwVVhEMFlYUHVpLUZ4RjJZT1dYQjR0Y3Jxd2tfVlpGQ1prUmVidDNQWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQOXFCcmU1TkZ3RVZEUWRHVldPWlEtbDd1RVhBeWdXMDcxZ2lmbzlIbU94WHNGUGo1MzJNd21GV1Z3NzBka3poaXBKYXdjS2p1NlE5QlZsMUxncHEtVXVibnhMeWtLODhpOGVhMWhQaUxMR001MGk1amRjUjA3bDg2ZzdmeU8xZkk0QjltOGdRa2p3d2NBWGpOTXhCVlBzQzlHQjVGa2tXS1pUa2RKMU9ZRWQzOS1MZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQWEhxMGhYTDZDVTBuQTlKZWpHT0FBNFk5eWlydGRnR3FQcW1FQW5rMFNzRm1jQ3lYTzB1X2ZQdDh2LVZ6RTRGVnh3SERxVkN6WmpwTl9WSzRjeWtDX2tsSEZicU1US3l1TzdXdjFmRG9GOVdGX3hWcEdzTFROcmxVcHB5NEtTNW5uakk2X00yQmZrb2lK?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Announces an Oversubscribed Private Placement of up", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxQV0JNMy10U0RrQUU4Um9GT09RZ0FYWkc1UFMtcmZtdFV4TTFYT2N0LTZzejFVX3hSQmttZDB6MUwwMnZidU9KUkI0SU1DTWVBLWlxWnpFY2k3RlFWWW00U05KZXVacm9BRmZHQnFuRFdSOG1rTlU1VkFtRFAtOG9FakVLU1dpZ2ZvejFHeDN3NmUwSk1uOUExbkMxSkRabDVQaHhjMUN0VDZYVFFUTGFwNUgtUDM5SjVUNFNzS0pNUzZMWjVzMHJzemk0ajAtMFExUGpPcFFrUW9LcVpiczN3NkFJZUFJUmV1OWJlMXByRDZlU2luQ045eEYxRWZ5M1NUeUhMTWVQSlg4a0JSNjhYMkowRWJWVHVSRkdjZWVCUmJRSS10UDlfeGNjYTBMYTFQUzlYZA?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9ZQjU5LVhFbThYT3BlV000VHpCZkJWYS1xQmxuZVdWQ05wdXBybzZ1U2c2MUZ0b3RJZjlZZmhBdWl2M2ZpNmhwNlZZUFVZOFNxWThJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:10:59+00:00", "published_display": "25 Apr 2025 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Announces Pricing of Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOUFZVNE1IWHdJUXFwUlFoSzA2QmNQZTFFblplanlpd2xYLXF3V2FTVFMyMnZUcUhMcVhCUFNJYzlnUTJLTFZwQjV0WXRrUWdxcXFaRU5vM1FIWnZ1VFhYNVVta0JJaVdFaUwwZm1hLVQzQXI2Uk1PeXY4OU5Md3ZXdHhyXzJTLUp3QzFvcHlGY2RSdlJ0b3FXUTlJeGJPQ1QwNU1RblIyTHRadjRDRV9PXzdKM0JkREd3UEtNblZCYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-10-10T07:00:00+00:00", "published_display": "10 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics (CAMP) Stock Forecast and Price Target 2026 $CAMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1IdWFNTHAtMmtzWi1DUVdvMkVYS3FQbE14RkhHQnVuYUdtb2JXTi1KNFpfY0pUX1pTRDE2R01LRTd2WFpQNVR0OFl6eTJMSlhaejlfZmpHTFk5LXczclVYUDhqc05Ddw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:51:13+00:00", "published_display": "11 May 2024 15:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis $CAMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5tTVZaY3lGR3VucTRwYy05c2Fkc0p1QTZNNVRMc2dXaDJOaXZJUzNmVTItSU9sRFozVkF4Z3Z6YmRyak91aW9IaFczSWliXzNIRGxaOTRvNUk2UQ?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-05T14:04:58+00:00", "published_display": "05 Jun 2015 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T12:53:38+00:00", "published_display": "18 Jul 2026 12:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "CAMP4 Therapeutics announced a non-qualified stock option grant to a new employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant involves 8,000 shares at an exercise price of $4.21 per share and will vest over a four-year period. This", "url": "https://www.globenewswire.com/fr/news-release/2026/07/17/3329275/0/en/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-18T04:10:55", "published_display": "18 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 New Hire Gets Option on 8,000 Shares at $4.21", "summary": "CAMP4 Therapeutics announced that its Board Compensation Committee granted a non-qualified stock option to a new employee to purchase 8,000 shares of common stock at an exercise price of $4.21 per share. This inducement grant, made under Nasdaq Listing Rule 5635(c)(4), has a 10-y", "url": "https://www.stocktitan.net/news/CAMP/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-qj27rqb7iosu.html", "source_name": "Stock Titan", "published_at": "2026-07-17T19:41:38", "published_display": "17 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?", "summary": "JPMorgan upgraded CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) to Overweight with a price target of $9, citing the potential undervaluation given the promise of CMP-002 for SYNGAP1-related disorder. The company also announced positive preclinical results for CMP-002, showing impr", "url": "https://www.insidermonkey.com/blog/is-camp4-therapeutics-corporation-camp-stock-undervalued-ahead-of-key-cmp-002-clinical-development-milestones-1793951/", "source_name": "Insider Monkey", "published_at": "2026-07-02T16:06:00", "published_display": "02 Jul 2026 16:06", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8 Best Up and Coming Pharmaceutical Stocks to Buy Now", "summary": "The article highlights CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) as a promising pharmaceutical stock, noting JPMorgan's upgrade to Overweight with a $9 price target due to potential of CMP-002 for SYNGAP1-related disorder. CAMP4's preclinical findings for CMP-002 showed signif", "url": "https://www.insidermonkey.com/blog/8-best-up-and-coming-pharmaceutical-stocks-to-buy-now-1792190/2/", "source_name": "Insider Monkey", "published_at": "2026-06-30T18:04:00", "published_display": "30 Jun 2026 18:04", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of CAMP4 Therapeutics Corp (CAMP), noting its current valuation score of 6.02, which ranks 364 out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -1.79, indicating a significant deviation from it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-26T21:09:20", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP - CAMP4 Therapeutics Corp Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for CAMP4 Therapeutics Corp (CAMP), including its last close price, market capitalization, income, sales, key financial ratios, and performance metrics. It lists insider and institutional ownership, profitability margins, and s", "url": "https://finviz.com/stock?t=CAMP&ta=1&p=d&ty=rv&b=2", "source_name": "Finviz", "published_at": "2026-06-23T09:39:56", "published_display": "23 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 lures 3 new hires with 39,000 stock options", "summary": "CAMP4 Therapeutics (Nasdaq:CAMP) has granted 39,000 non-qualified stock options to three new employees as an inducement to join the company. These options, with an exercise price of $3.96 per share, vest over four years with a 10-year term. This move aligns with Nasdaq Listing Ru", "url": "https://www.stocktitan.net/news/CAMP/camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-0o0c8fzbzbaj.html", "source_name": "Stock Titan", "published_at": "2026-06-19T20:09:17", "published_display": "19 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "CAMP4 Therapeutics, a clinical-stage biopharmaceutical company, announced stock option grants to three new employees as an inducement to employment. These grants, totaling 39,000 shares, are in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $3.96 per", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314891/0/en/camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T16:05:00", "published_display": "19 Jun 2026 16:05", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Institutional Confidence", "summary": "CAMP4 Therapeutics Corp (CAMP) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. This score reflects an institutional shareholding proportion of 82.01%, a quarter-over-quarter increase of 237.71%. Steven ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T16:40:16", "published_display": "18 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "TradingKey reports that CAMP4 Therapeutics Corp (CAMP) has a current financial score of 6.62, ranking 235 out of 388 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently saw a 50.82% year-over-year", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:12:59", "published_display": "18 Jun 2026 06:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "CAMP4 Therapeutics Corp (CAMP) has an earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry. Analysts have an average price target of $7.50 for the stock, with a consensus \"Buy\" rating based on 7 analysts. The company's expected revenue fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:12:59", "published_display": "18 Jun 2026 05:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides details on the dividend and stock split history for CAMP4 Therapeutics Corp (CAMP). It indicates that the company has distributed $0.00 in dividends over the past five years and has no historical stock split data available. The page also presents current sto", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-camp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T11:09:28", "published_display": "17 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Shares Rise After JPMorgan Upgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/camp4-therapeutics-shares-rise-jpmorgan-185644276.html", "source_name": "MT Newswires", "published_at": "2026-06-16T18:56:44+00:00", "published_display": "16 Jun 2026 18:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Upgrades CAMP4 Therapeutics to Overweight From Neutral, Adjusts PT to $9 From $5", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-upgrades-camp4-therapeutics-overweight-091952324.html", "source_name": "MT Newswires", "published_at": "2026-06-16T09:19:52+00:00", "published_display": "16 Jun 2026 09:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential", "summary": "JPMorgan has upgraded CAMP4 Therapeutics Corp (NASDAQ:CAMP) to Overweight and raised its price target to $9.00, citing the potential of its drug candidate CMP-002 for SYNGAP1-related disorder. The firm believes the stock is undervalued, anticipating CMP-002 will enter clinical tr", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-upgrades-camp4-therapeutics-stock-rating-on-cmp002-potential-93CH-4743907", "source_name": "Investing.com", "published_at": "2026-06-16T05:39:13", "published_display": "16 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike", "summary": "Camp4 Therapeutics director Stewart Murray was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. These options will vest fully on the earlier of the first anniversary of the grant date or the company's next annual meeting of stockho", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-95b370c4c6ff.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:13:38", "published_display": "16 Jun 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics director granted 28K options | CAMP Insider Trading", "summary": "Camp4 Therapeutics director and 10% owner Amir Nashat was granted 28,000 stock options with an exercise price of $4.34 per share; no cash was paid at the time of the grant. The options vest fully on the earlier of the first anniversary of the grant date or the company's next annu", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-0f0b08800288.html", "source_name": "Stock Titan", "published_at": "2026-06-13T02:09:16", "published_display": "13 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics (CAMP) director awarded 28,000 stock options", "summary": "Camp4 Therapeutics (CAMP) director Douglas E. Williams was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options will fully vest on the earlier of the first anniversary of the grant date or the company's next annual meeting,", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-fd33bb0225d3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:16", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics (CAMP) grants director 28,000 stock options", "summary": "Camp4 Therapeutics Corp. director Richard A. Young was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the company's next annual meeting, continge", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-121edaf1222b.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:16", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics director granted 28,000 options | CAMP Insider Trading", "summary": "Camp4 Therapeutics director Steven H. Holtzman was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options will vest on the earlier of the first anniversary of the grant date or the company's next annual shareholder meeting, p", "url": "https://www.stocktitan.net/sec-filings/CAMP/form-4-camp4-therapeutics-corp-insider-trading-activity-7d7e34867096.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:16", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan initiates CAMP4 Therapeutics stock with buy rating", "summary": "Chardan has initiated coverage on CAMP4 Therapeutics with a buy rating and a price target of $6.50, citing significant upside potential from its current trading price of $4.01. The biotechnology company, specializing in antisense oligonucleotides for neurodevelopmental disorders ", "url": "https://m.uk.investing.com/news/stock-market-news/chardan-initiates-camp4-therapeutics-stock-with-buy-rating-93CH-4721222?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T13:09:47", "published_display": "11 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan initiates CAMP4 Therapeutics stock with buy rating By Investing.com", "summary": "Chardan has initiated coverage on CAMP4 Therapeutics (NASDAQ:CAMP) with a buy rating and a price target of $6.50, citing significant upside potential from its current trading price of $4.01. The clinical-stage biotechnology company, supported by research from MIT's Whitehead Inst", "url": "https://au.investing.com/news/stock-market-news/chardan-initiates-camp4-therapeutics-stock-with-buy-rating-93CH-4479945", "source_name": "Investing.com Australia", "published_at": "2026-06-11T02:40:35", "published_display": "11 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP Initiated Coverage by Chardan Capital -- Rating Set to Buy", "summary": "Chardan Capital has initiated coverage on Camp4 Therapeutics (CAMP) with a \"Buy\" rating and a price target of $6.50, citing the company's pioneering work in RNA-based therapeutics for genetic diseases. Despite this positive outlook, Camp4 Therapeutics holds a low GF Score\u2122 of 8/1", "url": "https://www.gurufocus.com/news/8909851/camp-initiated-coverage-by-chardan-capital-rating-set-to-buy?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-10T15:09:47", "published_display": "10 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Initiates Camp4 Therapeutics at Buy With $6.50 Price Target", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/chardan-initiates-camp4-therapeutics-buy-104423485.html", "source_name": "MT Newswires", "published_at": "2026-06-10T10:44:23+00:00", "published_display": "10 Jun 2026 10:44", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation", "summary": "Camp4 Therapeutics (NASDAQ:CAMP) has seen its stock rise 114% in the last year despite not yet making a profit. The company has a cash runway of 3.8 years, with $99 million in cash and a cash burn of $26 million in the past year. Analysts are optimistic about its revenue growth o", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-were-not-too-125746501.html", "source_name": "Market source", "published_at": "2026-06-06T12:39:37", "published_display": "06 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP - CAMP4 Therapeutics Corp Options", "summary": "This page provides a detailed financial overview of CAMP4 Therapeutics Corp (CAMP), including its stock performance, key financial metrics, and company statistics. It covers areas such as market capitalization, income, sales, insider and institutional ownership, and various perfo", "url": "https://finviz.com/stock?t=CAMP&ty=oc", "source_name": "Finviz", "published_at": "2026-06-02T22:39:58", "published_display": "02 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP - CAMP4 Therapeutics Corp Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news for CAMP4 Therapeutics Corp (CAMP). It details the company's stock price, market capitalization, income, sales, and various financial ratios, along with insider transac", "url": "https://finviz.com/stock?t=CAMP", "source_name": "Finviz", "published_at": "2026-06-01T10:09:58", "published_display": "01 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New CAMP4 hire receives 5,000-share stock option grant", "summary": "CAMP4 Therapeutics (Nasdaq: CAMP) announced it granted a non-qualified stock option to a new employee to purchase 5,000 shares of common stock. This inducement award, granted under Nasdaq Listing Rule 5635(c)(4), has a 10-year term and an exercise price of $4.31, vesting over fou", "url": "https://www.stocktitan.net/news/CAMP/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-5w6x7yz1cca2.html", "source_name": "Stock Titan", "published_at": "2026-05-24T08:09:42", "published_display": "24 May 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNcE5WUGt0NDM0bmpUUUZ0RlZ1Y3VaNk5HNVE0dEEtU0dPVmF3bU9jMFdxTGJ6MjdtZ0psVnNvX3JrM0ZOdWtHOWtnRnJQZ3M3Y2Q4U0FNV2hkQXNocy1yMGRlTDZRdTV1cVZscDc1Vmg2Z0M1YzBVZXZDNDZocVhQRW9jeGNLRXJMNm5qLUQ3Tm9lYzdFeVBkSVBFbUhkRWFxbVFid2hTVTlDQ2NqMm9SRjdJeFNJUzNCc3lPdHZWZ3dwZjhEWUJqYkV5Z0VOSWoxTURVREVjVlNpVXNmLWdlQw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three new CAMP4 hires get stock options at $4.59 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQRi00WGdqb1pTNUs4bjUyZXd5azExd05aVWF4ekN0OTVGYm9sSHFibW9hZDV2Y3BHeGIxU1hRMHNBZDc1VDFfbml2X0NFUXNvcDF5Tll0eUpENWw3blVFNmVES2hKN1pfcE9BN01yS01hSWdXZllSUFBnLVdhTVVObW9ndWpIWi12WlI1d2pzaWo1cHEyUVJwVVhEMFlYUHVpLUZ4RjJZT1dYQjR0Y3Jxd2tfVlpGQ1prUmVidDNQWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQOXFCcmU1TkZ3RVZEUWRHVldPWlEtbDd1RVhBeWdXMDcxZ2lmbzlIbU94WHNGUGo1MzJNd21GV1Z3NzBka3poaXBKYXdjS2p1NlE5QlZsMUxncHEtVXVibnhMeWtLODhpOGVhMWhQaUxMR001MGk1amRjUjA3bDg2ZzdmeU8xZkk0QjltOGdRa2p3d2NBWGpOTXhCVlBzQzlHQjVGa2tXS1pUa2RKMU9ZRWQzOS1MZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQWEhxMGhYTDZDVTBuQTlKZWpHT0FBNFk5eWlydGRnR3FQcW1FQW5rMFNzRm1jQ3lYTzB1X2ZQdDh2LVZ6RTRGVnh3SERxVkN6WmpwTl9WSzRjeWtDX2tsSEZicU1US3l1TzdXdjFmRG9GOVdGX3hWcEdzTFROcmxVcHB5NEtTNW5uakk2X00yQmZrb2lK?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Announces an Oversubscribed Private Placement of up", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxQV0JNMy10U0RrQUU4Um9GT09RZ0FYWkc1UFMtcmZtdFV4TTFYT2N0LTZzejFVX3hSQmttZDB6MUwwMnZidU9KUkI0SU1DTWVBLWlxWnpFY2k3RlFWWW00U05KZXVacm9BRmZHQnFuRFdSOG1rTlU1VkFtRFAtOG9FakVLU1dpZ2ZvejFHeDN3NmUwSk1uOUExbkMxSkRabDVQaHhjMUN0VDZYVFFUTGFwNUgtUDM5SjVUNFNzS0pNUzZMWjVzMHJzemk0ajAtMFExUGpPcFFrUW9LcVpiczN3NkFJZUFJUmV1OWJlMXByRDZlU2luQ045eEYxRWZ5M1NUeUhMTWVQSlg4a0JSNjhYMkowRWJWVHVSRkdjZWVCUmJRSS10UDlfeGNjYTBMYTFQUzlYZA?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9ZQjU5LVhFbThYT3BlV000VHpCZkJWYS1xQmxuZVdWQ05wdXBybzZ1U2c2MUZ0b3RJZjlZZmhBdWl2M2ZpNmhwNlZZUFVZOFNxWThJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:10:59+00:00", "published_display": "25 Apr 2025 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Announces Pricing of Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOUFZVNE1IWHdJUXFwUlFoSzA2QmNQZTFFblplanlpd2xYLXF3V2FTVFMyMnZUcUhMcVhCUFNJYzlnUTJLTFZwQjV0WXRrUWdxcXFaRU5vM1FIWnZ1VFhYNVVta0JJaVdFaUwwZm1hLVQzQXI2Uk1PeXY4OU5Md3ZXdHhyXzJTLUp3QzFvcHlGY2RSdlJ0b3FXUTlJeGJPQ1QwNU1RblIyTHRadjRDRV9PXzdKM0JkREd3UEtNblZCYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-10-10T07:00:00+00:00", "published_display": "10 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics (CAMP) Stock Forecast and Price Target 2026 $CAMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1IdWFNTHAtMmtzWi1DUVdvMkVYS3FQbE14RkhHQnVuYUdtb2JXTi1KNFpfY0pUX1pTRDE2R01LRTd2WFpQNVR0OFl6eTJMSlhaejlfZmpHTFk5LXczclVYUDhqc05Ddw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:51:13+00:00", "published_display": "11 May 2024 15:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis $CAMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5tTVZaY3lGR3VucTRwYy05c2Fkc0p1QTZNNVRMc2dXaDJOaXZJUzNmVTItSU9sRFozVkF4Z3Z6YmRyak91aW9IaFczSWliXzNIRGxaOTRvNUk2UQ?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-05T14:04:58+00:00", "published_display": "05 Jun 2015 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 47, "sentiment_summary": {"positive": 21, "negative": 1, "neutral": 25, "score": 59, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.0, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 3.71, "latest_week": "2026-07-17", "one_week_move": -14.3, "four_week_move": -10.2, "twelve_week_move": -16.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.750072, "market_dynamics_buy_signal": false, "relative_strength": -14.310209, "fair_value_gap": -12.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.5644, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-14.3% over one week, -10.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "Insider Monkey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 9}, {"label": "Balance sheet", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-14.3% over one week, -10.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth"}], "updated_at": "2026-07-24T16:55:05.596192+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}